Company profile
CONTEXT THERAPEUTICS INC.
NASDAQ:CNTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ELACESTRANT | phase1_2 | — | 2 | terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06515613 | phase1 | recruiting | 2024-07-10 | 2028-05-31 | Context Therapeutics Inc. | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors |
| NCT07545122 | phase1 | recruiting | 2026-09-01 | 2030-01-01 | Context Therapeutics Inc. | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers |
| NCT06938711 | phase1_2 | withdrawn | 2023-06-01 | 2023-11-01 | Context Therapeutics Inc. | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer |
| NCT06756035 | phase1 | recruiting | 2025-03-31 | 2026-12-01 | Context Therapeutics Inc. | CT-95 in Advanced Cancers Associated With Mesothelin Expression |
| NCT05618613 | phase1_2 | terminated | 2022-12-02 | 2023-06-23 | Context Therapeutics Inc. | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer |
FDA applications (0)
No records yet.